1
|
Matsushita M, Kashiwazaki S, Kamiko S, Kobori M, Osada M, Kunieda H, Hirao M, Ichikawa D, Hattori Y. Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells. Pharmaceuticals (Basel) 2023; 16:1367. [PMID: 37895838 PMCID: PMC10609901 DOI: 10.3390/ph16101367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 09/08/2023] [Accepted: 09/22/2023] [Indexed: 10/29/2023] Open
Abstract
Several anti-cancer drugs are known to have immunomodulatory effects, including immunogenic cell death (ICD) of cancer cells. ICD is a form of apoptosis which is caused by the release of damage-associated molecular patterns (DAMPs), the uptake of cancer antigens by dendritic cells, and the activation of acquired immunity against cancer cells. ICD was originally reported in solid tumors, and there have been few reports on ICD in multiple myeloma (MM). Here, we showed that proteasome inhibitors, including carfilzomib, induce ICD in myeloma cells via an unfolded protein response pathway distinct from that in solid tumors. Additionally, we demonstrated the potential impact of ICD on the survival of patients with myeloma. ICD induced by proteasome inhibitors is expected to improve the prognosis of MM patients not only by its cytotoxic effects, but also by building strong immune memory response against MM cells in combination with other therapies, such as chimeric antigen receptor-T cell therapy.
Collapse
Affiliation(s)
- Maiko Matsushita
- Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
| | - Sho Kashiwazaki
- Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
| | - Satoshi Kamiko
- Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
| | - Michio Kobori
- Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
| | - Makoto Osada
- Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan; (M.O.)
| | - Hisako Kunieda
- Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan; (M.O.)
| | - Maki Hirao
- Department of Health Science, Faculty of Sports and Health Science, Daito Bunka University, Saitama 355-8501, Japan
| | - Daiju Ichikawa
- Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
| | - Yutaka Hattori
- Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan
- Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan; (M.O.)
| |
Collapse
|
2
|
Okayama M, Fujimori K, Sato M, Samata K, Kurita K, Sugiyama H, Suto Y, Iwasaki G, Yamada T, Kiuchi F, Ichikawa D, Matsushita M, Hirao M, Kunieda H, Yamazaki K, Hattori Y. GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c-MET tyrosine kinase. Cancer Med 2023; 12:9749-9759. [PMID: 36825580 PMCID: PMC10166914 DOI: 10.1002/cam4.5691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 01/30/2023] [Accepted: 02/01/2023] [Indexed: 02/25/2023] Open
Abstract
OBJECTIVE Despite the development of newly developed drugs, most multiple myeloma (MM) patients with high-risk cytogenetic abnormalities such as t(4;14) or del17p relapse at anin early stage of their clinical course. We previously reported that a natural product,komaroviquinone (KQN), isolated from the perennial semi-shrub Dracocephalum komarovi, i.e., komaroviquinone (KQN) and its derivative GTN024 induced the apoptosis of MM cells by producing reactive oxygen species (ROS), but both exhibited significant hematological toxicity. Aim of this study is to clarify anti-tumor activity, safety and pharmacokinetics of GTN057, an optimization compound of KQN in vivo. METHODS ICR/SCID xenograft model of KMS11, a t(4;14) translocation-positive MM cell line, was used for in vivo study. Mice pharmacokinetics of GTN057 and the degradation products were analyzed by LC-MS/MS. RESULTS Herein, our in vitro experiments revealed that GTN057 is much less toxic to normal hematopoietic cells, induced the apoptosis of both MM cell lines andpatient samples, including those with high-risk cytogenetic changes. A xenograft model of a high-risk MM cell line demonstrated that GTN057 significantly delayed the tumor growth with no apparent hematological or systemic toxicities in vivo. The pathological examination of GTN057-treated tumors in vivoshowed revealed apoptosis of MM cells and anti-angiogenesis. In addition to the production of ROS, GTN057 inhibited the downstream signaling of c-MET, a receptor tyrosine kinase a receptor forand hepatocyte growth factor (HGF) receptor. Thus, GTN057 is less toxic and is able tomay be a candidate drug for treating MM patients, via multifunctional mechanisms. We have also extensively studied the pharmacologyical analysis of GTN057. The metabolites of GTN057, (e.g.,such as GTN054), may also have anti-tumorantitumor activity. CONCLUSION Natural products or and their derivatives can could be good sources of antineoplastic drugs even for high-risk cancer.
Collapse
Affiliation(s)
- Mikio Okayama
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.,Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kota Fujimori
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Mariko Sato
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Koichi Samata
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Koki Kurita
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Hiromu Sugiyama
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Yutaka Suto
- Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan
| | - Genji Iwasaki
- Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan
| | - Taketo Yamada
- Department of Pathology, Saitama Medical University, Saitama, Japan
| | - Fumiyuki Kiuchi
- Division of Natural Medicines, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Daiju Ichikawa
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Maiko Matsushita
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Maki Hirao
- Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
| | - Hisako Kunieda
- Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
| | - Kohei Yamazaki
- Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
| | - Yutaka Hattori
- Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.,Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
| |
Collapse
|
3
|
Characteristics of a Novel Target Antigen Against Myeloma Cells for Immunotherapy. Vaccines (Basel) 2020; 8:vaccines8040579. [PMID: 33023190 PMCID: PMC7712752 DOI: 10.3390/vaccines8040579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 09/20/2020] [Accepted: 09/28/2020] [Indexed: 11/17/2022] Open
Abstract
Despite the availability of therapeutic treatments, multiple myeloma is an incurable haematological disorder. In this study, we aimed to clarify the role of CXorf48 as a therapeutic target in multiple myeloma. Based on a previously identified HLA-A*24:02-restiricted epitope from this novel cancer/testis antigen, we characterized the activities of cytotoxic T lymphocytes (CTLs) specific to this antigen against myeloma cells and evaluated the effects of demethylating agents in increasing antigen expression and enhancing the cytotoxic activity of CTLs. CXorf48 expression was examined by reverse transcription polymerase chain reaction (RT-PCR) using nine myeloma cell lines. Cell lines with low CXorf48 expression were treated by demethylating agents (DMAs), 5-azacytidine (5-aza), and 5-aza-2’-deoxycytidine (DAC) to evaluate gene expression using quantitative RT-PCR. Furthermore, CXorf48-specific CTLs were induced from peripheral blood mononuclear cells of HLA-A*24:02-positive healthy donors to evaluate antigen recognition using ELISpot and 51Cr cytotoxicity assays. CXorf48 was widely expressed in myeloma cells, and gene expression was significantly increased by DMAs. Furthermore, CXorf48-specific CTLs recognized DMA-treated myeloma cells. These findings suggest that CXorf48 is a useful target for immunotherapy, such as vaccination, in combination with demethylating agents for the treatment of patients with myeloma.
Collapse
|
4
|
Okayama M, Kitabatake S, Sato M, Fujimori K, Ichikawa D, Matsushita M, Suto Y, Iwasaki G, Yamada T, Kiuchi F, Hirao M, Kunieda H, Osada M, Okamoto S, Hattori Y. A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress. Biochem Biophys Res Commun 2018; 505:787-793. [DOI: 10.1016/j.bbrc.2018.09.177] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Accepted: 09/28/2018] [Indexed: 01/16/2023]
|
5
|
Aida S, Hozumi M, Ichikawa D, Iida K, Yonemura Y, Tabata N, Yamada T, Matsushita M, Sugai T, Yanagawa H, Hattori Y. A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest. Biochem Biophys Res Commun 2017; 493:514-520. [DOI: 10.1016/j.bbrc.2017.08.159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Accepted: 08/31/2017] [Indexed: 11/30/2022]
|
6
|
Suto Y, Sato M, Fujimori K, Kitabatake S, Okayama M, Ichikawa D, Matsushita M, Yamagiwa N, Iwasaki G, Kiuchi F, Hattori Y. Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma. Bioorg Med Chem Lett 2017; 27:4558-4563. [PMID: 28882484 DOI: 10.1016/j.bmcl.2017.08.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 08/22/2017] [Accepted: 08/25/2017] [Indexed: 12/21/2022]
Abstract
Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs. However, high-risk MM cases that are refractory to novel drugs remain, and further optimization of chemotherapeutics is urgently needed. We had achieved asymmetric total synthesis of komaroviquinone, which is a natural product from the plant Dracocephalum komarovi. Similar to several leading antitumor agents that have been developed from natural compounds, we describe the antitumor activity and cytotoxicity of komaroviquinone and related compounds in bone marrow cells. Our data suggested that komaroviquinone-related agents have potential as starting compounds for anticancer drug development.
Collapse
Affiliation(s)
- Yutaka Suto
- Faculty of Pharmacy, Takasaki University of Health and Welfare, Gunma 370-0033, Japan.
| | - Mariko Sato
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan
| | - Kota Fujimori
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan
| | - Shotaro Kitabatake
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan
| | - Mikio Okayama
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan; Division of Hematology, Department of Internal Medicine, Keio University, Tokyo 160-8582, Japan
| | - Daiju Ichikawa
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan
| | - Maiko Matsushita
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan
| | - Noriyuki Yamagiwa
- Faculty of Pharmacy, Takasaki University of Health and Welfare, Gunma 370-0033, Japan
| | - Genji Iwasaki
- Faculty of Pharmacy, Takasaki University of Health and Welfare, Gunma 370-0033, Japan
| | - Fumiyuki Kiuchi
- Keio University Faculty of Pharmacy, Natural Medicines, Tokyo 105-8512, Japan
| | - Yutaka Hattori
- Clinical Physiology & Therapeutics, Keio University Faculty of Pharmacy, Tokyo 105-8512, Japan
| |
Collapse
|
7
|
Matsushita M, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, Yanagawa H, Oikawa T, Matsuo K, Du W, Yamada T, Hozumi M, Ichikawa D, Hattori Y. A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. PLoS One 2015; 10:e0116135. [PMID: 25617756 PMCID: PMC4305313 DOI: 10.1371/journal.pone.0116135] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Accepted: 11/24/2014] [Indexed: 01/14/2023] Open
Abstract
Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the Cmax was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.
Collapse
Affiliation(s)
- Maiko Matsushita
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Yoshie Ozaki
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Yuka Hasegawa
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Fukiko Terada
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Noriko Tabata
- Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan
| | - Hirokazu Shiheido
- Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan
| | - Hiroshi Yanagawa
- Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan
| | - Tsukasa Oikawa
- Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan
| | - Koichi Matsuo
- Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan
| | - Wenlin Du
- Department of Pathology, School of Medicine, Keio University, Tokyo, Japan
| | - Taketo Yamada
- Department of Pathology, School of Medicine, Keio University, Tokyo, Japan
| | - Masashi Hozumi
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Daiju Ichikawa
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Yutaka Hattori
- Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan
- * E-mail:
| |
Collapse
|
8
|
Vyhlídalová I, Uherková L, Pleschnerová M, Špička I, Březinová J, Michalová K, Čermáková K, Polanská V, Jedelský PL, Hamšíková E, Kuželová K, Stöckbauer P. Characterization of a new human plasma cell leukemia cell line UHKT-944. Eur J Haematol 2015; 95:352-60. [PMID: 25600340 DOI: 10.1111/ejh.12505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/11/2014] [Indexed: 11/27/2022]
Abstract
OBJECTIVE A new interleukin-6 (IL-6)-dependent plasma cell leukemia cell line UHKT-944 was established from bone marrow cells derived from a 55-yr-old man with plasma cell leukemia. RESULTS The cell line possesses phenotypic characteristics of plasma cells including the production of a monoclonal immunoglobulin IgA1-kappa. VH3-9 region of IgVH genes was rearranged and somatically hypermutated. The UHKT-944 cells were found to be negative for most of tested B-cell, T-cell, and myeloid markers. According to cytogenetic analysis, the cells were classified as near tetraploid with several numerical and structural abnormalities including the t(14;20) involving IgH locus. CONCLUSION The established permanent plasma cell leukemia cell line is a suitable model for the study of cellular and molecular mechanisms of pathogenesis of this rare malignant disease.
Collapse
Affiliation(s)
- Ilona Vyhlídalová
- Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion (IHBT), Prague, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
| | - Lenka Uherková
- Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion (IHBT), Prague, Czech Republic
| | - Markéta Pleschnerová
- Department of Immunology, Faculty of Science, Charles University, Prague, Czech Republic
| | - Ivan Špička
- 1st Department of Internal Medicine, Division of Hematology, General Faculty Hospital, Charles University, Prague, Czech Republic
| | - Jana Březinová
- Department of Cytogenetics, IHBT, Prague, Czech Republic
| | - Kyra Michalová
- Department of Cytogenetics, IHBT, Prague, Czech Republic
| | - Kamila Čermáková
- Leukemia PCR Diagnostics Laboratory, IHBT, Prague, Czech Republic
| | | | - Petr L Jedelský
- Faculty of Science, Charles University, Prague, Czech Republic.,Faculty of Arts, Charles University, Prague, Czech Republic
| | - Eva Hamšíková
- Department of Experimental Virology, IHBT, Prague, Czech Republic
| | - Kateřina Kuželová
- Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion (IHBT), Prague, Czech Republic
| | - Petr Stöckbauer
- Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion (IHBT), Prague, Czech Republic
| |
Collapse
|